UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The metalloprotease ADAMTS4 generates N-truncated Aβ4–x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer’s disease

Acta neuropathologica, 2019-02, Vol.137 (2), p.239-257

2019

Volltextzugriff (PDF)

Gamma-secretase modulation and its promise for Alzheimer's disease: a rationale for drug discovery

Current topics in medicinal chemistry, 2008, Vol.8 (1), p.34-37

Beher, Dirk

2008

Volltextzugriff (PDF)

Generation and characterization of a rabbit monoclonal antibody site-specific for tau O-GlcNAcylated at serine 400

FEBS letters, 2013-11, Vol.587 (22), p.3722-3728

2013

Volltextzugriff (PDF)

Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease

Alzheimer's research & therapy, 2012-03, Vol.4 (2), p.9-9

2012

Volltextzugriff (PDF)

Homodimerization of Amyloid Precursor Protein and Its Implication in the Amyloidogenic Pathway of Alzheimer's Disease

The Journal of biological chemistry, 2001-09, Vol.276 (36), p.33923-33929

2001

Volltextzugriff (PDF)

C‐terminal PAL motif of presenilin and presenilin homologues required for normal active site conformation

Journal of neurochemistry, 2006-01, Vol.96 (1), p.218-227

2006

Volltextzugriff (PDF)

Selective Modulation of Aβ42 Production in Alzheimers Disease: Non-Steroidal Anti-Inflammatory Drugs and Beyond

Current pharmaceutical design, 2006-11, Vol.12 (33), p.4337-4355

2006

Volltextzugriff (PDF)

The Amyloid Precursor Protein of Alzheimer's Disease in the Reduction of Copper(II) to Copper(I)

Science (American Association for the Advancement of Science), 1996-03, Vol.271 (5254), p.1406-1409

1996

Volltextzugriff (PDF)

LRRTM3 Promotes Processing of Amyloid-Precursor Protein by BACE1 and Is a Positional Candidate Gene for Late-Onset Alzheimer's Disease

Proceedings of the National Academy of Sciences - PNAS, 2006-11, Vol.103 (47), p.17967-17972

2006

Volltextzugriff (PDF)

Resveratrol is Not a Direct Activator of SIRT1 Enzyme Activity

Chemical biology & drug design, 2009-12, Vol.74 (6), p.619-624

2009

Volltextzugriff (PDF)

The Intramembrane Cleavage Site of the Amyloid Precursor Protein Depends on the Length of Its Transmembrane Domain

Proceedings of the National Academy of Sciences - PNAS, 2002-02, Vol.99 (3), p.1365-1370

2002

Volltextzugriff (PDF)

Regulation of Amyloid Protein Precursor (APP) Binding to Collagen and Mapping of the Binding Sites on APP and Collagen Type I (∗)

The Journal of biological chemistry, 1996-01, Vol.271 (3), p.1613-1620

1996

Volltextzugriff (PDF)

Fatty acids increase presenilin-1 levels and γ-secretase activity in PSwt-1 cells

Journal of lipid research, 2004-12, Vol.45 (12), p.2368-2376

2004

Volltextzugriff (PDF)

Pathogenic Aβ production by heterozygous PSEN1 mutations is intrinsic to the mutant protein and not mediated by conformational hindrance of wild-type PSEN1

The Journal of biological chemistry, 2023-08, Vol.299 (8), p.104997-104997, Article 104997

2023

Volltextzugriff (PDF)

O‑GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α‑Synuclein Proteinopathies

ACS chemical neuroscience, 2022-04, Vol.13 (8), p.1296-1314

2022

Volltextzugriff (PDF)

Alzheimer's disease mutations in APP but not γ-secretase modulators affect epsilon-cleavage-dependent AICD production

Nature communications, 2013, Vol.4 (1), p.2246-2246, Article 2246

2013

Volltextzugriff (PDF)

Substrate determinants in the C99 juxtamembrane domains differentially affect [gamma]-secretase cleavage specificity and modulator pharmacology

Journal of neurochemistry, 2013-05, Vol.125 (4), p.610

2013

Volltextzugriff (PDF)

The Role of γ-Secretase Activating Protein (GSAP) and Imatinib in the Regulation of γ-Secretase Activity and Amyloid-β Generation

The Journal of biological chemistry, 2013-01, Vol.288 (4), p.2521-2531

2013

Volltextzugriff (PDF)

Substrate determinants in the C99 juxtamembrane domains differentially affect γ–secretase cleavage specificity and modulator pharmacology

Journal of neurochemistry, 2013-05, Vol.125 (4), p.610-619

2013

Volltextzugriff (PDF)

Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism

The Journal of biological chemistry, 2004-10, Vol.279 (42), p.43419-43426

2004

Volltextzugriff (PDF)

L-685,458, an Aspartyl Protease Transition State Mimic, Is a Potent Inhibitor of Amyloid β-Protein Precursor γ-Secretase Activity

Biochemistry (Easton), 2000-08, Vol.39 (30), p.8698-8704

2000

Volltextzugriff (PDF)

Gamma-secretase as a therapeutic target for the treatment of Alzheimer's disease

Current pharmaceutical design, 2005-01, Vol.11 (26), p.3363-3382

2005

Volltextzugriff (PDF)

O3‐04‐04: Pharmacological intervention with the novel o‐glcnacase inhibitor ASN‐561 reduces pathological tau in transgenic mice

Alzheimer's & dementia, 2015-07, Vol.11 (7S_Part_5), p.P227-P227

2015

Volltextzugriff (PDF)

1 – 25 von 85

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(83)
Mit Volltextzugriff
(77)

Publikationsform

Artikel
(85)

Sprache

Englisch
(85)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Current directions in tau research: Highlights from Tau 2020

The metalloprotease ADAMTS4 generates N-truncated Aβ4–x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer’s disease

Gamma-secretase modulation and its promise for Alzheimer's disease: a rationale for drug discovery

Generation and characterization of a rabbit monoclonal antibody site-specific for tau O-GlcNAcylated at serine 400

Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease

Homodimerization of Amyloid Precursor Protein and Its Implication in the Amyloidogenic Pathway of Alzheimer's Disease

C‐terminal PAL motif of presenilin and presenilin homologues required for normal active site conformation

Selective Modulation of Aβ42 Production in Alzheimers Disease: Non-Steroidal Anti-Inflammatory Drugs and Beyond

The Amyloid Precursor Protein of Alzheimer's Disease in the Reduction of Copper(II) to Copper(I)

LRRTM3 Promotes Processing of Amyloid-Precursor Protein by BACE1 and Is a Positional Candidate Gene for Late-Onset Alzheimer's Disease

Resveratrol is Not a Direct Activator of SIRT1 Enzyme Activity

The Intramembrane Cleavage Site of the Amyloid Precursor Protein Depends on the Length of Its Transmembrane Domain

Regulation of Amyloid Protein Precursor (APP) Binding to Collagen and Mapping of the Binding Sites on APP and Collagen Type I (∗)

Fatty acids increase presenilin-1 levels and γ-secretase activity in PSwt-1 cells

Pathogenic Aβ production by heterozygous PSEN1 mutations is intrinsic to the mutant protein and not mediated by conformational hindrance of wild-type PSEN1

O‑GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α‑Synuclein Proteinopathies

Alzheimer's disease mutations in APP but not γ-secretase modulators affect epsilon-cleavage-dependent AICD production

Substrate determinants in the C99 juxtamembrane domains differentially affect [gamma]-secretase cleavage specificity and modulator pharmacology

A framework for translating tauopathy therapeutics: Drug discovery to clinical trials

The Role of γ-Secretase Activating Protein (GSAP) and Imatinib in the Regulation of γ-Secretase Activity and Amyloid-β Generation

Substrate determinants in the C99 juxtamembrane domains differentially affect γ–secretase cleavage specificity and modulator pharmacology

Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism

L-685,458, an Aspartyl Protease Transition State Mimic, Is a Potent Inhibitor of Amyloid β-Protein Precursor γ-Secretase Activity

Gamma-secretase as a therapeutic target for the treatment of Alzheimer's disease

O3‐04‐04: Pharmacological intervention with the novel o‐glcnacase inhibitor ASN‐561 reduces pathological tau in transgenic mice

Suchergebnisse filtern